In clusters 2 and 3 that rely on OXPHOS, OXPHOS inhibitors would increase ICI sensibility in melanoma patients that progressed with PD-1 and CTLA4 blockade (58, 59) and in melanoma brain metastases that rely on OXPHOS (60). Here, CTLA4 is linked to melanoma.